

Haematologica  
HAEMATOL/2019/236992  
Version 3

Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in  
IDH1 mutant acute myeloid leukemia

Anuhar Chaturvedi, Charu Gupta, Razif Gabdoulline, Nora M. Borchert,  
Ramya Goparaju, Stefan Kaulfuss, Kerstin Görlich, Renate  
Schottmann, Basem Othman, Julia Welzenbach, Olaf Panknin, Markus  
Wagner, Robert Geffers, Arnold Ganser, Felicitas Thol, Michael Jeffers,  
Andrea Haegebarth, and Michael Heuser

Disclosures: Chaturvedi and M. Heuser received research support to their University from Bayer AG. S. Kaulfuss, and M. Jeffers are employees of Bayer AG. M. Wagner, O. Panknin, and A. Haegebarth are employees and equity owners of Bayer AG. All other authors have no conflict of interest. This work was supported by funding from Bayer AG, an ERC grant under the European Union's Horizon 2020 research and innovation programme (No. 638035), by grant 70112697 from Deutsche Krebshilfe; the German Federal Ministry of Education and Research grant 01EO0802 (IFB-Tx); and DFG grants HE 5240/5-1, HE 5240/6-1 and HE5240/6-2.

Contributions: A.C. and M.H. conceived and designed the study. A.C., C.G., N.B., R.Go., K.G., R.S., B.O., J.W., and R.Ge. collected the data. A.C., C.G., R.Gab., and M.H. analyzed and assembled the data. S.K., O.P., M.W., M.J., and A.H. provided critical reagents. F.T., A.G. and M.H. collected patient samples and provided the patient data. A.C. and M.H. wrote the manuscript. All authors reviewed the data and edited and approved the final version of the manuscript.